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Introduction
Adiponectin is a material made of white adipose tissue 
which is itself made of collagen-like proteins with 244 
amino acids (1,2). It has a gene-protein character and its 
plasma level in a healthy individual is 2–20 μg/mL (1,2). 
This cytokine, in fact, forms 1% of the total serum protein 
(1-3). In normal health conditions without a renal disease, 
the synthesis and secretion of the cytokine is negatively 
proportional to body weight which is due to negative 
feedback effects of serum levels on the expression of 
genes that make fat tissue (2-4). Adiponectin is excreted 
via glomerular filtration (3-5). Adiponectin plays a 
protective role against atherosclerosis, thus it prevents the 
attachment of monocytes to endothelial (1-4). Moreover, 
in normal body condition, adiponectin has a significant 
effect on insulin function and its level of secretion. It also 
affects the optimized use and storage of energy in the body 
and can regulate the energy metabolism and catabolism in 
mitochondria (2-5).
Specifically, adiponectin increases in patients with chronic 
renal failure undergoing hemodialysis and peritoneal 
dialysis (2-5). Research has shown that adiponectin 
levels in hemodialysis patients is 2.5-3 times more than 
that in healthy people. Such an increase is associated 
with decreased renal function, disorder in the regulation 
of the type and rate of serum levels, and disorder in 
adiponectin receptors (3-7). In such a condition, increased 
adiponectin is considered as one of the new risk factors 
for atherosclerosis, and it changes into one of the most 
important causes of mortality in these patients (6-8). It has 
also been stated that, there is an association between serum 
adiponectin level and other risk factors for atherosclerosis, 
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including traditional and new factors (1-4). Studies suggest 
that in patients with chronic renal failure adiponectin is 
a predictor of mortality and progression of renal failure 
(1-6). This suggests that the biological protective effect of 
adiponectin against cardiovascular diseases is decreased 
in uremic patients (2-5).
In chronic inflammatory conditions such as chronic heart 
failure or kidney insufficiency, the consumption of body 
sources of energy including fat and protein will increase. 
This process reduces the weight and makes the body lean, 
thus speeds up mortality in patients .In this situation, 
adiponectin causes and aggravates the hypercatabolic 
syndrome (2-8).
It is reported that such an increase is associated with loss 
of energy and protein and increased fluid volume in this 
group of patients (4-9). A study on nephrotic syndrome 
showed that the increase in serum adiponectin level 
has a strong positive association with risk of metabolic 
syndrome and proteinuria (10-14).
In a study on patients with chronic renal failure who 
were affected by type 1 diabetes, the association between 
serum adiponectin and albuminuria and creatinine levels 
was assessed. The results showed a positive relationship 
between increased level of serum adiponectin with 
albuminuria and increased serum creatinine (10-15). 
Objectives
Considering the importance of adiponectin in 
inflammatory conditions and due to the lack of information 
about its relationship with the parameters influencing 
inflammatory conditions in hemodialysis non-diabetic 
patients, this study was designed to assess the association 
between serum adiponectin with various parameters in in 
a group of non-diabetic hemodialysis patients.
Patients and Methods
Type of study and sampling method
To carry out this study, we recruited 73 non-diabetic 
hemodialysis patients who referred to hemodialysis ward 
in Hajar hospital in Shahrekord in 2012. Of all, 33 patients 
 Implication for health policy/practice/research/
medical education
Adiponectin is a hormone secreted by adipose tissue. 
In uremic condition, it not only loses its protective role 
against atherosclerosis, but also becomes a risk factor. 
It can influence other risk factors for atherosclerosis 
and can also cause and exacerbate the hypercatabolic 
condition. Consequently it can result in indiscriminate 
use of body energy – protein and can be a predictor of 
morbidity and mortality in these patients. As a result, 
finding of exact connections between this cytokines and 
the risk factors of atherosclerosis and hypercatabolism 
may help to introduce serum adiponectin as a 
measurable and important marker for atherosclerosis 
and may be used as an index for prognosis of mortality 
in this type of patients.
were female and 40 patients were male. Their age range 
was between 13 to 91 years. Following a standard protocol, 
before hemodialysis, systolic and diastolic blood pressures 
of all patients (per mm Hg) were measured two times with 
a time interval of 15 minutes. Weights of patients with the 
minimum clothes and without shoes were measured by a 
calibrated scale and were recorded in kilograms. Heights 
of patients without shoes, in a vertical position, while their 
heels were completely close to the wall, were measured 
using a cotton meter that was attached to the wall and the 
measured heights were recorded in meters. Body Mass 
Index (BMI) was calculated through dividing weight (kg) 
by the square of height (m2). Waist size was measured by 
a meter three centimeter (cm) above the belly button in 
cm. Waist circumference in cm was measured using a 
cotton meter.
To collect adiponectin blood samples and other samples, 
a needle 18 was used and the blood was taken from the 
dialysis site. Accordingly, if dialysis was performed by 
permcath, first, a few milliliters of blood was aspirated 
to remove the heparin and then the samples were taken 
from the arterial line. Otherwise, if the dialysis had been 
performed by fistula or graft, the blood samples were 
taken from the area where it was determined for dialysis. 
To test serum glucose, cholesterol, triglycerides (via 
enzymatic method per mg/dl), and total cholesterol 
(by immunoturbidimetry method per mg/dl) samples 
were sent to hospital laboratory. To determine serum 
adiponectin level, serums were immediately isolated after 
blood sampling and stored at -80°C to -70°C until testing. 
In our laboratory, serum adiponectin level was measured 
per μg/ml by ELISA method and using a kit supplied by 
Orgenium Company, UK. 
Ethical considerations
The primary research plan was approved by the Research 
Committee of Hajar hospital and school of medicine. 
Moreover, ethics committee of Shahrekord University of 
Medical Sciences also approved the plan. Before beginning 
the study, written informed consent was obtained from all 
patients who participated in the study. All information 
about patient was coded and kept confidential.
Data analysis
Data obtained from patients that had been recorded 
in checklists and the data which was collected from the 
laboratory tests were analyzed using SPSS version 16. 
Chi-square test was used for descriptive parameters. The 
association between adiponectin levels in patients with 
other parameters was assessed by calculating Pearson’s 
correlation coefficient and related graphs were plotted 
using Excel software. The correlation coefficient below 5% 
was considered as a statistically significant value.
Results
Table 1 presents the details about the patients who were 
enrolled in the study. Of all 73 non-diabetic hemodialysis 
patients who were studied, 54.80% were male and 45.20% 
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were female. The mean age of patients was 57.07; the 
youngest and oldest patients were 13 and 91 years old, 
respectively.
Table 1 presents patients’ data. The results suggest that 
mean serum adiponectin level was 10.56±3.88 μg/
ml. In addition, the minimum and maximum levels of 
serum adiponectin level in patients were 32.0 and 17.41 
μg/ml (Table 1). The mean weight of patients was 58.38 
kg, the mean BMI was 21.92 kg/m2, and the mean waist 
and abdominal circumference were 87.73 and 92.19 cm, 
respectively (Table 1).
As shown in Table 1, adiponectin level was negatively and 
insignificantly associated with age of patients. Additionally, 
there was a significant negative association between serum 
adiponectin and body weight and BMI (P < 0.05, and R 
was -0.48 and -0.55, respectively) (Figures 1 and 2).
The correlation coefficients between adiponectin and 
waist and abdominal circumference, respectively, were 
-0.25 and -0.40, which was significant at the 5% level 
(Figures 3 and 4).
Mean systolic and diastolic blood pressures were 124.38 
mm Hg and 70.28 mm Hg, respectively (Table 1). There 
was no significant association between blood pressure and 
Table 1. Patients’ characteristics
Characteristic Mean Standard Deviation  (SD) Minimum Maximum
Age (year) 57.07 19.96 13.00 91.00
Male (%) 54.80 50.11 0 100
Adiponectin (μg/ml) 10.56 3.88 0.32 17.41
Weight (kg) 58.38 14.33 31.00 103.00
Body mass index (kg/m2) 21.92 3.79 14.74 33.33
Waist circumference (cm) 87.73 10.77 65.00 140.00
Abdominal circumference (cm) 92.19 10.43 59.00 115.00
Systolic blood pressure (mm Hg) 124.38 21.98 90.00 190.00
Diastolic blood pressure (mm Hg) 70.27 9.86 60.00 90.00
Sodium (mg/dl) 140.93 2.75 134.00 146
Potassium (mg/dl) 4.98 0.69 3.00 7.50
Blood Urea Nitrogen (mg/dl) 64.94 18.52 26.00 112.00
Creatinine (mg/dl) 8.62 2.88 2.80 10.00
Calcium (mg/dl) 9.00 0.54 7.50 11.00
Phosphorus (mg/dl) 5.11 1.13 2.80 10.00
Fasting glucose (mg/dl) 82.29 10.09 65.00 110.00
Triglycerides (mg/dl) 150.91 95.92 45.00 581.00
Cholesterol (mg/dl) 171.93 41.24 71.00 283.00
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Figure 1. Association between serum adiponectin level and 
weight of non-diabetic hemodialysis patients
Figure 2. Association between serum adiponectin level and body 
mass index in non-diabetic hemodialysis patients
Figure 3. Association between serum adiponectin level and waist 
circumference in non-diabetic hemodialysis patients
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adiponectin at the 5% statistical level (Table 2).
As shown in Table 2, there was no significant correction 
between serum adiponectin with levels of serum 
parameters including sodium, potassium, calcium 
phosphorus and also blood urea nitrogen (BUN) and 
creatinine (P > 0.05).
Mean fasting glucose level was 82.29 mg/dl (Table 1) and 
it had no significant association with serum adiponectin 
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level too (P > 0.05; Table 2).
Discussion
Based on the results of this study, serum adiponectin 
level in hemodialysis patients had a negative significant 
association with weight and BMI. Moreover, waist and 
abdominal circumference had a significant negative 
association with serum adiponectin level. Adiponectin 
is a cytokine protein - collagen which is secreted only 
from adipose tissue (1-5). Recent studies have shown that 
adipose tissue is not only an energy storage tissue, but also 
it is like an endocrine tissue which generates hormones 
and uses them to connect with other tissues (3-9). 
Adiponectin is produced by a set of adipose tissue genes 
(10-18). Adiponectin makes its effects on other organs via 
adiponectin receptors type I and II (5-10).
Adiponectin creation is regulated by a negative feedback 
relationship between serum adiponectin levels and adipose 
tissue (11-17). Adiponectin exists in plasma in three 
forms: with low, medium, and high molecular weights (8-
14). However, high molecular weight adiponectin is more 
effective in terms of function (3-8). Adiponectin is excreted 
via kidney glomerular filtration (12-18). In healthy people, 
adiponectin has a protective role against atherosclerosis; 
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Figure 4. Association between serum adiponectin level and 
abdominal circumference in non-diabetic hemodialysis patients
Table 2. Association between adiponectin with various 
characteristics of hemodialysis patients (N= 73)
Characteristic P value  r
Age (year) 0.130 -0.180
Weight (kg) 0.001*** -0.480
Body mass index (kg/m2) 0.001*** -0.550
Waist  circumference  (cm) 0.037* -0.250
Abdominal circumference (cm) 0.004** -0.400
Systolic blood pressure (mmHg) 0.710 0.040
Diastolic blood pressure (mmHg) 0.960 0.007
Sodium (mg/dl) 0.170 0.160
Potassium (mg/dl) 0.990 0.001
Blood Urea Nitrogen (mg/dl) 0.240 0.140
Creatinine (mg/dl) 0.490 0.080
Calcium (mg/dl) 0.920 -0.010
Phosphorus (mg/dl) 0.170 0.160
Fasting glucose (mg/dl) 0.230 0.140
*, ** and *** indicate significance at levels of 5, 1 and 0.1%, 
respectively.
however after the development of atherosclerotic plaques, 
it not only loses its protective role (especially in basic 
inflammatory conditions such as uremia), but also 
together with other inflammatory cytokines becomes 
a cause of development and progress of atherosclerotic 
plaques (16-18). Studies suggest that serum adiponectin 
level in hemodialysis patients is 4 to 5 times higher than 
that in healthy people (12-19). Due to higher expression 
of adiponectin mRNA, adiponectin is more increased in 
yellow adipose tissues of end-stage renal failure patients 
than in healthy subjects (12-18). Such an increase can lead 
to increased risk of death due to cardiovascular problems 
(18-22). In basic inflammatory conditions such as uremia, 
hyper catabolic conditions emerge which consume the 
energy of the body and subcutaneous white fat (source of 
energy storage in body). In contrast, the yellow adipose 
tissue, in which inflammatory cells are accumulated and 
inflammatory cytokines are generated, are formed around 
body organs with low weights and sizes (22-25) Therefore, 
chronic inflammatory condition such as uremia can 
lead to weight loss, decrease BMI and reduce waist 
and abdominal circumference. On the other hand, the 
production of adiponectin, as an inflammatory cytokine, 
increases and causes an inverse relationship between 
serum adiponectin level and weight, body mass index, 
and waist and abdominal circumference. Recent studies 
suggest a positive significant association between plasma 
adiponectin level and severe systemic weight loss, which is 
a predictor of early mortality (20-27). Other investigations 
also state that serum adiponectin level in patients with 
heart failure is associated with severe weight loss (24-27).
Conclusion
Adiponectin is a hormone secreted by adipose tissue. In 
uremic conditions, it not only loses its protective role 
against atherosclerosis, but also becomes a risk factor. 
Hence it can influence other risk factors for atherosclerosis 
and can also cause and exacerbate the hypercatabolic 
condition, consequently it can result in indiscriminate 
use of body energy – protein and can be a predictor of 
morbidity and mortality in these patients. As a result, 
finding exact connections between this cytokines and the 
risk factors of atherosclerosis and hypercatabolism may 
help introducing serum adiponectin as a measurable and 
important marker for atherosclerosis and may be used as 
an index for prognosis of mortality in this type of patients.
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